MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenteration
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2025.08.001 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Luca Sorrentino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: luca.sorrentino@istitutotumori.mi.it. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local, Pelvic Exenteration, Rectal Neoplasms. Die Arbeit nennt 24 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Locally recurrent rectal cancers (LRRC) require exenterative surgery and pelvic re-irradiation to achieve R0 margins, which are the strongest predictor of survival. Data on immune checkpoint inhibitors (ICIs) in deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) LRRC are scarce. AIMS: To assess efficacy and short-term outcomes of pelvic exenteration and chemotherapy/(re)chemoradiation vs. ICIs in dMMR/MSI-H LRRC patients. METHODS: A multicenter study was conducted including patients affected by dMMR/MSI-H LRRC treated from 2009 to 2024 at 3 Italian centers. Short-term outcomes were assessed, including the rate of exenterative procedures, definitive ostomy rate, and quality of life issues. 3-yr progression-free survival (3y-PFS) was also analyzed. RESULTS: Eight patients were treated with ICI and 6 with standard treatment. Pelvic exenteration was performed in 66.7 % of cases in the standard treatment group vs. 12.5 % with ICI (p = 0.04). The definitive stoma rates were respectively 66.7 % and 12.5 % (p = 0.04). Quality of life was affected in 80.0 % of patients undergoing exenterative surgery, mainly related to urinary infections and/or fistula. 3-yr PFS was 51.4 % with ICI vs. 33.3 % with standard treatment (HR 0.35, p = 0.13). CONCLUSION: The use of ICIs might be an effective treatment for dMMR/MSI-H LRRC, avoiding pelvic exenteration and its consequences in the majority of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: luca.sorrentino@istitutotumori.mi.it.
- Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
- Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
- Medical Oncology 1, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.
- Colorectal Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: filippo.pietrantonio@istitutotumori.mi.it.
Zitieren
APA
Sorrentino, L., Nasca, V., Daveri, E., Lonardi, S., Bergamo, F., Intini, R., Scardino, A., Montroni, I., & Pietrantonio, F. (2025). MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenteration. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.08.001
Vancouver
Sorrentino L, Nasca V, Daveri E, Lonardi S, Bergamo F, Intini R, et al. MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenteration. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.08.001
BibTeX
@article{Sorrentino2025,
author = {Sorrentino, Luca and Nasca, Vincenzo and Daveri, Elena and Lonardi, Sara and Bergamo, Francesca and Intini, Rossana and Scardino, Andrea and Montroni, Isacco and Pietrantonio, Filippo},
title = {MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenteration},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2025.08.001}
}
EUVIMED